The Potential and Limitations of p38MAPK as a Drug Target for the Treatment of Hematological Malignancies

Publisher： Bentham Science Publishers

E-ISSN： 1873-5592|11|7|823-833

ISSN： 1389-4501

Source： Current Drug Targets, Vol.11, Iss.7, 2010-07, pp. : 823-833

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

p38 MAPK: A Potential Target of Chronic Pain

By  

Current Medicinal Chemistry, Vol. 21, Iss. 38, 2014-01 ,pp. : 4405-4418

Bentham Science Publishers

Access to resources Recommend Favorite

Potential Role of PKC Inhibitors in the Treatment of Hematological Malignancies

By  

Current Pharmaceutical Design, Vol. 14, Iss. 21, 2008-07 ,pp. : 2075-2084

Bentham Science Publishers

Access to resources Recommend Favorite

The Immunoproteasome as a Therapeutic Target for Hematological Malignancies

By  

Current Cancer Drug Targets, Vol. 14, Iss. 6, 2014-07 ,pp. : 537-548

Bentham Science Publishers

Access to resources Recommend Favorite

Rational Design of Novel Potential p38 MAPK Inhibitors with Drug-like Properties Using Pharmacophore and Similarity-based Virtual Screening Procedures

By  

Current Bioactive Compounds, Vol. 9, Iss. 1, 2013-03 ,pp. : 3-13

Bentham Science Publishers

Access to resources Recommend Favorite

The Potential of p38 MAPK Inhibitors to Modulate Periodontal Infections

By  

Current Drug Metabolism, Vol. 10, Iss. 1, 2009-01 ,pp. : 55-67

Bentham Science Publishers

Access to resources Recommend Favorite